Recent Developments in Rare Ovarian Carcinosarcoma: Literature Review and Case Report.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Ovarian Carcinosarcoma With Heterologous Chondrosarcomatous Differentiation: A Case Report and Review of Literature.Cureus · 2026
   Article
2. Sustained disease control in ovarian carcinosarcoma treated with postoperative hyperthermic intraperitoneal chemotherapy and targeted maintenance: a case report.Frontiers in medicine · 2026
   Article
3. The development of ovarian carcinosarcoma from serous tubal intraepithelial carcinoma: an immunohistochemical case report with literature review.Frontiers in oncology · 2026
   Article
4. Stage IVB ovarian carcinosarcoma in BRCA wild-type patients: two case reports of unexpected long-term remission.Frontiers in oncology · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as